Evolocumab has no Effects on Heart Failure with Reduced Ejection Fraction Injury Biomarkers: The EVO-HF Trial
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2932 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Antoni Bayes-Genis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Hauptthemen laut MEDLINE: Heart Failure, Coronary Artery Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aim
Patients with heart failure with reduced ejection fraction (HFrEF) have not been shown to benefit from statins. We hypothesized that, by limiting disease progression in stable HFrEF of ischaemic etiology, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab could reduce circulating troponin levels, a surrogate biomarker of myocyte injury and atherosclerosis progression. Methods and results The EVO-HF multicentre prospective randomized trial compared evolocumab (420 mg/month administered subcutaneously) plus guideline-directed medical therapy (GDMT; n = 17) versus GDMT alone (n = 22) for 1 year in patients with stable coronary artery disease and left ventricular ejection fraction (LVEF) <40%, ischaemic aetiology, New York Heart Association class II, N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥400 pg/ml, high-sensitivity troponin T (hs-TnT) >10 pg/ml, low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl. The primary endpoint was change in hs-TnT concentration. Secondary endpoints included NT-proBNP, interleukin-1 receptor-like 1 (ST2), high-sensitivity C-reactive protein (hs-CRP), LDL, low-density lipoprotein receptor (LDLR), high-density lipoprotein cholesterol (HDL-C), and PCSK9 levels at 1 year. Patients were mainly Caucasian (71.8%), male (79.5%), relatively young (mean age 68.1 ± 9.4 years), with a mean LVEF of 30.4 ± 6.5%, and managed with contemporary treatments. No significant changes in hs-TnT levels were observed in any group at 1 year. NT-proBNP and ST2 levels decreased in the GDMT plus evolocumab group (p = 0.045 and p = 0.008, respectively), without changes in hs-CRP, HDL-C, or LDLR. Total and LDL-C decreased in both groups, significantly higher in the intervention group (p = 0.003), and PCSK9 levels increased in the intervention group.
Conclusions
This prospective randomized pilot trial, although with the limitation of the small sample size, does not support the benefit of evolocumab in reducing troponin levels in patients with elevated LDL-C levels, history of coronary artery disease, and stable HFrEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
- Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Barcelona, Spain.
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
- Hospital Universitario Virgen del Rocío, Sevilla, Spain.
- Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Valencia, Spain.
ORCID-Profile: Antoni Bayes-Genis
Zitieren
APA
Bayes-Genis, A., Lupón, J., Revuelta-Lopez, E., Llibre, C., Gastelurrutia, P., Domingo, M., Cediel, G., Codina, P., Santiago-Vacas, E., Rangel-Sousa, D., Fernández-Cisnal, A., Miñana, G., Mollar, A., & Núñez, J. (2023). Evolocumab has no Effects on Heart Failure with Reduced Ejection Fraction Injury Biomarkers: The EVO-HF Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2932
Vancouver
Bayes-Genis A, Lupón J, Revuelta-Lopez E, Llibre C, Gastelurrutia P, Domingo M, et al. Evolocumab has no Effects on Heart Failure with Reduced Ejection Fraction Injury Biomarkers: The EVO-HF Trial. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2932
BibTeX
@article{BayesGenis2023,
author = {Bayes-Genis, Antoni and Lupón, Josep and Revuelta-Lopez, Elena and Llibre, Cinta and Gastelurrutia, Paloma and Domingo, Mar and Cediel, Germán and Codina, Pau and Santiago-Vacas, Evelyn and Rangel-Sousa, Diego and Fernández-Cisnal, Agustín and Miñana, Gema and Mollar, Anna and Núñez, Julio},
title = {Evolocumab has no Effects on Heart Failure with Reduced Ejection Fraction Injury Biomarkers: The EVO-HF Trial},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2932}
}
EUVIMED